A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Strengths of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Strengths of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Abediterol (Primary) ; Indacaterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Almirall S.A.
  • Most Recent Events

    • 08 Sep 2013 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met.
    • 08 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 06 Jun 2012 Rseults have been reported in an Almirall media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top